Process of Aging. Manifestation of Estrogen and/or Androgen Loss: Symptoms Over Time. Estrogen Decrease and Its Impact on Sexual Functioning
|
|
- Gladys Riley
- 6 years ago
- Views:
Transcription
1 Impact of Vulvovaginal Atrophy on Quality of Life and Sexuality Process of Aging physical health sexual activity Sexual function and aging desire androgen levels Michael L. Krychman MD Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine Associate Clinical Professor UCI Department of Gynecology Oncology NAMS Annual Meeting Dallas Texas 2013 Delayed orgasm Fear of sexual or anorgasmia relations Dyspareunia and vulvar/vaginal atrophy estrogen levels Sherwin BB et al. Psychosom Med. 1987;49: Sarrel PM et al. J Reprod Med. 1998;43: JL Alexander, 2 Manifestation of Estrogen and/or Androgen Loss: Symptoms Over Time Lila Nachtigall, M.D. Discussing Urogenital Atrophy Oncology Volume 13, 1999 Range of Estrogen secretion levels (pg/ml) Short-term symptoms Long-term symptoms Onset insidious with significant individual variability Mood, sleep, and/or Hot flushes acute cognitive changes Urogenital symptoms Decreased sexual activity Decreased arousal Decreased libido Among 2000 postmenopausal women in any given year: 20 will develop heart disease 11 will develop bone loss 6 will develop breast cancer 3 will develop endometrial cancer But nearly 100% will develop urogenital atrophy. Proceedings of a conference held in Charlottesville Virginia, September 21-23, Age (y). 3 4 Estrogen Decrease and Its Impact on Sexual Functioning Estrogen Has Effects on All Tissue Components of the Vulvovaginal Area Estrogen decrease impacts the integrity of the female reproductive tract tissues Dyspareunia Decreased vaginal lubrication Atrophic vaginitis Decreased blood flow to reproductive organs Diminished vasocongestion Blood flow to the vulva (as measured by Doppler ultrasound velocimetry) increased by 50% when estrogen was administered to postmenopausal women Sarrel PM. Obstet Gynnecol. 1990:75:4:26S-30S. Epithelia (skin, vaginal) Promotes epithelial maturation and proliferation Maturation index relates to estrogen levels Ratio of parabasal to intermediate to superficials cells Skin appendages Blood vessels Increases vascularity and blood flow Nerves Specialized glands Stimulates glandular secretions (eg, Bartholin s gland) Sarrel PM et al. Fertil Steril. 1997;68: JL Alexander, 5 Utian WH. Front Hormone Res. 1975;3:
2 7 Perivaginal Blood Flow During Estrogen Replacement Therapy Vulvovaginal Changes Can Lead to Sexual Symptoms Milliwatts (mw) Baseline 1 Month 3 Months 6 Months Increase in blood flow values in women estrogen-deprived at baseline, and then administered conjugated estrogens. Vaginal dryness Dyspareunia Reduced or absent pleasure from direct genital stimulation Urinary symptoms Urgency, frequency, and possibly incontinence Predisposition to vulvar, vaginal, and lower UTIs If atrophy severe Vaginal shortening and narrowing Possible introital stenosis Prevents penetration or causes significant pain and/or bleeding from attempted penetration Possibly frequent sexual arousal and activity promotes genital health Wilbur JE et al. Menopause. 1998;5: Semmens J et al. JAMA. 1982;248: Leiblum S et al. JAMA. 1983;249: What is Urogenital Atrophy (UA)? Dyspareunia & Bladder Symptoms UA is a condition of associated tissue and organ deterioration/dryness UA is due to estrogen depletion and is associated with urinary and vaginal symptoms UA is chronic and progressive UA contributes to atrophic vaginitis (AV) and sexual dysfunction in women Coital pain causes: Tightened, defensive myalgic pelvic floor Pelvic Floor Hypertonus Reflex inhibition of periurethral vascular arousal Mechanical urethral trauma Keil K. Current Women s Health Reports.2002,2: O Connell HE et al. J.Urol. 1998;159: D Amati G et al. J.Urol. 2002;60: Slide courtesy of A Graziottin, Clinical Symptoms of Urogenital Atrophy Symptoms That May Accompany Urogenital Atrophy Urethral Weak urinary stream Recurrent UTI Urge incontinence Urgency Frequency Urethral caruncle (lesions) Urethral erythema Friable urothelium Urinary Frequency Urgency Incontinence Frequent UTI Dysuria Vaginal Dryness with dyspareunia Burning Occasional bleeding Recurrent vaginitis or bacterial vaginosis Itching Pain Vaginal pressure Malodorous discharge Endocrine Aspects of Female Sexual Dysfunctin Workgroup. Second International Consultation on Erectile and Sexual Dysfunctions; Paris, France; June 28-July 1, UTI = urinary tract infection. Keil K. Current Women s Health Reports 2002,2: Bachmann GA et al. Am Fam Physician 2000;;1:
3 13 Pelvic Floor Hypoestrogenism VVA is strongly Associated with FSD among Sexually Active Postmenopausal Women Levine et al: Menopause 15;4: Decreased connective tissue Decreased elastic tissue Increased fatty infiltration Cellular atrophy Nerve degeneration Reduced smooth muscle tone Menopause Epidemiology Study is cross sectional population based study of women years of age. Arizona Sexual Experience Study used Cross-sectional, population-based study of 1,480 sexually active, postmenopausal women Prevalence of vulvovaginal atrophy (57%) & FSD( 55%) Women with FSD were 3.84 times more likely to have vuvlovaginal atrophy than women without FSD. Women with sexual dysfunction ~4X more likely to also have vulvovaginal atrophy Endocrine Aspects of Female Sexual Dysfunction Workgroup. Second International Consultation on Erectile and Sexual Dysfunctions; Paris, France; June 28-July 1, Conclusion: Reducing symptoms of one condition may also relieve symptoms of the other What Do Patient Surveys Tell Us about VVA and QOL. ReVeal Survey (2008) Pfizer ReVeal ( Revealing Vaginal Effects at Mid Life) Healthy Women NovoNordisk VIVA ( Vaginal Health Insight, Views and Attitudes) CLOSER ( Clarifying Vaginal Atrophy Impact on Sex and Relationships) Shionogi REVIVE (REal Women s VIews of Treatment Options for Menopausal Vulvar/Vaginal ChangEs) Consisted of a phone survey among a representative sample of 1,006 PMW and an online survey of 602 HCP who treat postmenopausal women While most PMW surveyed recognized the importance of their sexual health, about 50% agreed that they refrain from talking about their sexual health/ intimacy with others 1/4 PMW surveyed experience dyspareunia at least sometimes. Even though it is painful, approximately 3/4 of these women engage in sex at least once a month, and one out of three engage in painful sex at least once weekly Healthy Women (2011) 56% of the postmenopausal women surveyed indicated they have experienced vaginal dryness. Among those women who reported experiencing vaginal dryness, 82% reported that their vaginal dryness is bothersome, with 20% reporting that their vaginal dryness bothers them either a lot or a great deal. 17% of women reported that their vaginal dryness did not bother them at all Negative Impact On Sexual Health But even if women are not discussing them, vaginal symptoms are having a negative impact on their sexual health. 63% who reported experiencing painful intercourse indicated that they avoid intimate situations because of their symptoms 70% who reported experiencing painful intercourse indicated their condition puts at least some strain on their sexual relationship with their partner 64% who reported experiencing vaginal dryness or 62% painful intercourse said they have learned to live with vaginal dryness/painful intercourse and have come to accept it
4 The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) Survey: Implications of Vaginal Discomfort in Postmenopausal Women and in Male Partners. Nappi RE, et al. JSM 2013: Sept 10 (9) % of the postmenopausal women surveyed who reported experiencing painful intercourse indicated they still engage in intercourse even though it is painful, 40% engaging in intercourse at least once a week. 73% said they engage in painful intercourse because of their partner 80% report that vaginal dryness impacted sexual frequency 70% are less sexual now as compared to before menopause Results: 28% percent of women did not tell their partners when they first encountered vaginal discomfort, Having sex less often (women: 58%, men: 61%), less satisfying sex (women: 49%, men: 28%), and putting off having sex (women: 35%, men: 14%) were the main effects of VA. Intimacy avoidance was attributed to painful sex (women: 55%, men: 61%) and women's reduced sexual desire (women: 46%, men: 43%). Conclusions: VA has an adverse emotional and physical impact on postmenopausal women and their partners. VVA and Impact VVA has a big impact on a woman s relationship with her significant other (Husbands sometimes force their wives to seek medical help) VVA is more about sexual intimacy than loss of youth Some women deal with VVA by doing everything they can to avoid intimacy (e.g. waking up early before husband, intentionally putting themselves in situations that are not sexually inducing) VVA takes away a woman s sense of sexual spontaneity VVA also affects women in partaking in physical activities, such as biking, walking and running VVA also impacts a woman s enjoyment of life and her temperament Enjoyment of sex Sexual spontaneity Ability to be intimate Relationship w/ partner Sleeping Temperament Enjoyment of life Seeking new relationship Traveling Athletic activities Everyday activities Social activities Ability to work Women without a partner are more impacted by VVA impacts a woman s Sex Life and non-sexual aspects of life 22 Therapy Benefits Is Local Really Local? Maintains lubrication through production and regulation of mucosal and glandular secretions Promotes organ and tissue integrity Mucosal and epithelial health Elasticity of connective tissues Smooth muscle function Blood flow and parenchymal perfusion ph control for flora-friendly environment Acidifies vaginal ph through uptake regulation of proton secretion via apical membrane of ectocervical epithelial cells Kendall et. al. cautions that vaginal estradiol is contraindicated in postmenopausal women on adjuvant aromatase inhibitors1. Labrie et. al. demonstrate that even small doses of vaginal preparations Vagifem 25 µg; Premarin Vaginal Cream result in significant systemic absorption through estrogen naive vaginas(2). Naessen et al showed that 7.5 µg/24h could improve the lipid profile and bone density without affecting the endometrium3-5. Bachmann GA et al. Am Fam Physician. 2000;61: Belchetz PE. N Engl J Med. 1994;330: Keil K. Current Women s Health Reports. 2002,2: Gorodeski G et al. Endocrinology. 2005;146; Kendall A, et. al. Ann Oncol 2006;17: Labrie F, et. al. Menopause 2009;16: Naessen T, et. al. J Clin Endocrinol Metab 2001;86: ; Am J Obstet Gynecol 1997;177: ; Am J Obstet Gynecol 2002;186:
5 25 VVA: Medical Need That Is Not Fully Addressed Premenopausal women taking anti-estrogens or who have medical/surgical conditions that result in decreased estrogen levels are susceptible Cancer Chemo/radiation therapies Surgery/Hysterectomy/Oophorectomy Breast cancer patients 54% of patients on tamoxifen report sexual dysfunction Increased incontinence and vaginal dryness, decreased sexual activity Atrophic Vaginitis: Chronic and Progressive Early detection of signs and symptoms of vaginal atrophy is important VVA will likely worsen if left untreated Dyspareunia may lead to sexual dysfunction VVA impacts sexuality and QOL Treatment is considered efficacious and is well documented Mortimer JE et al. J Clin Oncol ;17: Ganz PA et al. J Natl Cancer Inst ;94: ASK You cannot treat a problem if you do not know that one exists TELL Your health care professional cannot help you if he or she does not know there is a problem. 27
Year: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationNew Treatments for Vaginal Health. Sarah Azad, MD El Camino Women s Medical Group
New Treatments for Vaginal Health There s Hope Sarah Azad, MD El Camino Women s Medical Group The Genitrourinary Syndrome of Menopause (GSM) Problems with genital health secondary to the changes that occur
More informationLaser CO2: una terapia ambulatoriale innovativa nel trattamento delle disfunzioni sessuali femminili
Obstetrics and Gynaecology Unit Functional Unit of Urogynaecology Vita-Salute San Raffaele University and San Raffaele Hospital Milan Italy Laser CO2: una terapia ambulatoriale innovativa nel trattamento
More informationFemTouch Treatment for Improving Vulvovaginal Health
FemTouch Treatment for Improving Vulvovaginal Health Dr. M. Marziali MD PhD in Gynecology and Obstetric Introduction Vulvovaginal atrophy (VVA) accompanies the natural aging of the vagina and affects up
More informationInnovations in the Management of Dyspareunia
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationVaginal atrophy is a common condition
original article Oman Medical Journal [2017], Vol. 32, No. 1: 15 19 Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women Maitri Shah 1 *, Zalak Karena 1, Sangita V. Patel
More informationGP Education Series Women s cancers. GP Education Day 11 July 2016
GP Education Series Women s cancers GP Education Day 11 July 2016 Sexual Consequences of Treatment for Women s Cancers Dr Isabel White Clinical Research Fellow in Psychosexual Practice The Royal Marsden
More informationSEXUAL PAIN Home messages, a summary from Presentations, moderated Posters and Podiums
SEXUAL PAIN Home messages, a summary from Presentations, moderated Posters and Podiums María Luisa Banfi, MD Gynecologist, Sexologist Montevideo, Uruguay, South America CHICAGO 2012,SMS- ISSM, World Meeting
More informationDr. Maliheh Keshvari
1 Dr. Maliheh Keshvari Assistant professor of Urology Fellowship in Female Urology Mashhad University of Medical Sciences 2 Female Sexual Function and Dysfunction 3 It was not until recently that urologists
More informationThere are a variety of ways to address VVA. Keep yourself healthy, avoid irritants to the vulva and vagina, and use moisturizers and lubricants.
What is VulvoVaginal Atrophy? VulvoVaginal Atrophy, or VVA for short, is also called genitourinary syndrome of menopause. VVA is a condition where the skin of the vagina and vulva becomes thin, dry and
More informationEnergy Based Therapies in Gynecology and Vaginal Health: Update on CO 2
Energy Based Therapies in Gynecology and Vaginal Health: Update on CO 2 Eric R. Sokol MD Associate Professor of Obstetrics and Gynecology Associate Professor of Urology, by Courtesy Co-Director, Urogynecology
More informationSexual dysfunction: Is it all about hormones?
Sexual dysfunction: Is it all about hormones? Angelica Lindén Hirschberg, MD, PhD, Professor Department of Women s and Children s Health, Karolinska Institutet and Karolinska University Hospital, Stockholm,
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationSexual dysfunction in women with cancer: Navigating intimacy and intercourse between women and their partners
Sexual dysfunction in women with cancer: Navigating intimacy and intercourse between women and their partners Don S. Dizon, MD, FACP Clinical Co-Director, Gynecologic Oncology Founder and Director, The
More informationHaelle T. Changing the conversation about hormone therapy in menopause. Medscape, 2017; accessed
Pelvic PT Distance Journal Club: November 2018 (Moderator: MJ Strauhal PT, DPT, BCB- PMD) Topic: Why should pelvic PT s be knowledgeable of menopausal changes in the urogenital region and the history of
More informationDisease (diabetic neuropathy, multiple sclerosis, tumors, and, rarely, tertiary syphilis)
COURSES ARTICLE - THERAPYTOOLS.US Individual Planning: A Treatment Plan Overview for Adult Men with Sexual Performance Problems Individual Planning: A Treatment Plan Overview for Adult Men with Sexual
More informationErin E. Stevens, MD Chair, Department of Gynecologic Oncology Billings Clinic Cancer Center January 18, 2017
Erin E. Stevens, MD Chair, Department of Gynecologic Oncology Billings Clinic Cancer Center January 18, 2017 Objectives Define what's normal Define female sexual dysfunction Identify the causes of female
More informationRenewing Intimacy & Sexuality after Gynecologic Cancer
Renewing Intimacy & Sexuality after Gynecologic Cancer foundationforwomenscancer.org Over 90,000 women are diagnosed with a gynecologic cancer each year. The challenge for a woman with cancer and her healthcare
More informationSexological aspects of genital pain
Sexological aspects of genital pain Annamaria Giraldi, professor, MD, PHD Sexological Clinic, Psychiatric Centre Copenhagen 1 Disclosures Speaker: Eli Lilly, Pfizer Consultant: Eli Lilly,Palatin 2 Agenda
More informationMenopause Symptoms and Management: After Breast Cancer
Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a
More informationOriginal Article INTRODUCTION
Original Article A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012 Pardis Hosseinzadeh,
More informationBody image and sexuality issues after surgery or cancer
Body image and sexuality issues after surgery or cancer Sharon L. Bober, Ph.D. Director, Sexual Health Program Perini Family Survivors Center Dana-Farber Cancer Institute June 26, 2010 Why doesn t sex
More informationDyspareunia: Best Practices in Counseling, Diagnosis, and Therapy
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMenopause Matters. Equity Office Staff Seminar 14 November 2018
Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationTherapy and Sexual Health
Menopausal hormone therapy and sexual health Earn 3 CPD Points online Menopausal Hormone Therapy and Sexual Health Key messages Dr Tobie De Villiers Consultant Gynaecologist Panorama MediClinic Department
More informationUse of vaginal estrogen in Danish women: a nationwide cross-sectional study
AOGS ORIGINAL RESEARCH ARTICLE Use of vaginal estrogen in Danish women: a nationwide cross-sectional study AMANI MEAIDI 1,, IRINA GOUKASIAN & OEJVIND LIDEGAARD 1 1 Department of Gynecology, Rigshospitalet
More informationVVA : new therapeutic options? BMS october 2017 A Pintiaux
VVA : new therapeutic options? BMS october 2017 A Pintiaux Disclosures Member of the european board of TEVA without personal gain No conflict of interest for this presentation VVA Vulvar and vaginal atrophy
More informationLeslie R. Schover, PhD Department of Behavioral Science
Causes and Treatments of Low Sexual Desire in Breast Cancer Survivors Leslie R. Schover, PhD Department of Behavioral Science IMPORTANCE OF SEX TO BREAST CANCER SURVIVORS Livestrong 2006 Post-Treatment
More informationDyspareunia Associated with Vulvovaginal Atrophy: Innovations in Counseling, Diagnosis, and Management
SUPPLEMENT TO FREE 1 CME Credit To receive CME credit, please read the articles and go to www.omniaeducation.com/dysparenuia to access the posttest and evaluation or see the back of this supplement for
More informationA Non-Hormonal Approach to Preventing Vulvovaginal Atrophy from Aromatase Inhibitors (AIs)
A Non-Hormonal Approach to Preventing Vulvovaginal Atrophy from Aromatase Inhibitors (AIs) Leslie R. Schover, PhD Department of Behavioral Science Funded by the Duncan Family Institute for Cancer Prevention
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationWomen s Sexual Interest/Desire Disorder : Implications of New Definition
Women s Sexual Interest/Desire Disorder : Implications of New Definition Rosemary Basson MD FRCP(UK) Vancouver General Hospital University of British Columbia Vancouver, Canada 1 New Model of Sex Response
More information9/26/2016. Disclosures. Genitourinary Syndrome of Menopause: Novel Term for Common Conditions. Objectives ISSWSH NAMS CONSENSUS CONFERENCE
Genitourinary Syndrome of Menopause: Disclosures Novel Term for Common Conditions Research, Consultant, and/or Speaker Risa Kagan, MD, FACOG, CCD, NCMP Clinical Professor, Department of Obstetrics, Gynecology,
More informationAtrophic Vaginitis. Mimi Clarke Secor CHAPTER 23
Atrophic Vaginitis CHAPTER 23 Mimi Clarke Secor I. Atrophic vaginitis explained. A. Statistics. 1. Statistics indicate that 45 million women are menopausal and that this number is growing as baby boomers
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationFEMININE INTIMATE CARE
FEMININE INTIMATE CARE The role of the pharmacist Dr Trudy Smith Vaginal Health Vagina sensitive area Just like GIT, also contain flora Vaginal flora Maintain healthy ph (4.5) Lactobacilli (aerobic) Automatic
More informationNAMS in the News 2016
NAMS in the News 2016 Menopause in the News This is great support showing that being sedentary is not only not good for your health, it is not good for your menopause symptoms, said Dr. JoAnn Pinkerton,
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationVulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations
CLINICAL OBSTETRICS AND GYNECOLOGY Volume 58, Number 3, 476 491 Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations AHINOAM LEV-SAGIE, MD Department of Obstetrics
More informationManagement of Menopausal Symptoms in Patients with Breast Cancer. Mike Dixon Edinburgh Breast Unit
Management of Menopausal Symptoms in Patients with Breast Cancer Mike Dixon Edinburgh Breast Unit Menopausal symptoms have a major impact on Quality of Life Variety of Symptoms associated with the Menopause
More informationSex Cells The effect of hormones on peri- and post- menopausal female sexuality Dr. Cathy Caron November 24, 2011
Sex Cells The effect of hormones on peri- and post- menopausal female sexuality Dr. Cathy Caron November 24, 2011 Is sex over at menopause? Older adults are having sex 51% of women ages 50 to 59 report
More informationWomen s Intimacy, Sexuality and Relationship Issues After Cancer
Women s Intimacy, Sexuality and Relationship Issues After Cancer Sylvie Aubin, Ph.D. Segal Cancer Centre Jewish General Hospital McGill University Objectives Acknowledge changes in intimacy and sexuality
More informationFemale Sexual Dysfunction: Clinical approach
Female Sexual Dysfunction: Clinical approach - What Nurses want to know - Alessandra Graziottin MD Director, Center of Gynecology and Medical Sexology H.San Raffaele Resnati, Milano, Italy Co-Director,
More informationPresented by: Helena Green Clinical Sexologist/Counsellor.
Female Sexuality Presented by: Helena Green Clinical Sexologist/Counsellor helena@relate-sexology.com.au www.insyncforlife.com.au 02/05/2018 UWA IMED2208: Issues in women's reproductive health Clinical
More informationPAINFUL URINATION CAUSES & NATURAL REMEDY. Dr. Bestman Anyatonwu
LIBRACIN NATURAL MEDICINE IND. LTD PAINFUL URINATION CAUSES & NATURAL REMEDY Dr. Bestman Anyatonwu MEANING Painful urination is a broad term that describes discomfort during urination. This pain may originate
More informationLET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy
THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry
More informationVoiding Diary. Begin recording upon rising in the morning and continue for a full 24 hours.
Urodvnamics Your physician has scheduled you for a test called URODYNAMICS. This test is a series of different measurements of bladder function and can be used to determine the cause of a variety of bladder
More informationLow sexual desire: Appropriate use of testosterone in menopausal women
Low sexual desire: Appropriate use of testosterone in menopausal women Low-dose testosterone treatment may be considered for HSDD in carefully selected menopausal women after standard therapies have been
More informationSummary of the risk management plan (RMP) for Senshio (ospemifene)
EMA/736568/2014 Summary of the risk management plan (RMP) for Senshio (ospemifene) This is a summary of the risk management plan (RMP) for Senshio, which details the measures to be taken in order to ensure
More informationBy Milena Mincigrucci*, Costante Donati Sarti**, Angelamaria Becorpi***, Massimo Milani, and Gianluca Botta
Results of the VALYD* study A multicenter, epidemiological, observational, prospective study of vaginal atrophy and quality By Milena Mincigrucci*, Costante Donati Sarti**, Angelamaria Becorpi***, Massimo
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationGenitourinary Symptoms of Menopause (GSM) Effects on Sexual Function
Genitourinary Symptoms of Menopause (GSM) Effects on Sexual Function Amanda Clark MD MCR NCMP Urogynecologist Co-authors: Joanna Bulkley PhD, Kate Beadle WHNP, NCMP, Michael Leo PhD, Ashley Stoneburner
More informationUnderstanding Women's Sexuality after Bladder Cancer webinar. Part I: The Physical Impact
Understanding Women's Sexuality after Bladder Cancer webinar Tuesday, December 1, 2015 Part I: The Physical Impact Presented by LaShon Day received her Masters of Science as a Physician s Assistant at
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationAmy Siston, Ph.D. July 9, 2017
Amy Siston, Ph.D. July 9, 2017 Prevalence of Sexual Dysfunction Non-Cancer Population Ovarian Cancer Population 43% 30-100% Common Sexual Issues DESIRE: 25-59% no/low sexual desire AROUSAL: 24-60% difficulty
More informationResilient Intimacy. Richa Sood, M.D.
Resilient Intimacy Richa Sood, M.D. Disclosures No financial conflicts My specialty is Female Sexual Dysfunction Common Questions What is normal sexuality, and how does it change with medical illness?
More informationSexuality After the Diagnosis of Ovarian Cancer
Sexuality After the Diagnosis of Ovarian Cancer June La Valleur, MD, FACOG, Sexual Health Counselor Associate Professor, Ret., University of Minnesota Medical School Sexual Health Consultant at Skyhill
More informationLucy Guerra MD MPH FACP FHM Division Director & Associate Professor Internal Medicine
Lucy Guerra MD MPH FACP FHM Division Director & Associate Professor Internal Medicine Disclosures I have no financial, personal, or familial associations to disclose. Learner Objectives Develop a basic
More informationSexuality and Sexual Dysfunction in Women
Sexuality and Sexual Dysfunction in Women Denise M.S. Willers, MD Associate Professor of Obstetrics and Gynecology Washington University School of Medicine Disclosures No financial disclosures to make
More informationInterventions to Address Sexual Problems in People with Cancer
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Interventions to Address Sexual Problems in People with Cancer L. Barbera, C. Zwaal, D. Elterman, K. McPherson,
More informationFemale Sexuality Sheryl A. Kingsberg, Ph.D.
Female Sexuality Sheryl A. Kingsberg, Ph.D. Professor of Reproductive Biology Case Western Reserve University School of Medicine Chief, Division of Behavioral Medicine Department of OB/GYN University Hospitals
More informationSexuality. Renewing Intimacy and. After Gynecologic Cancer. Gynecologic Cancer Foundation. Women s Cancer Network Web Site:
Gynecologic Cancer Foundation 401 North Michigan Avenue Chicago, IL 60611 Tel: 312.644.6610 Fax: 312.527.6658 E-mail: gcf@sba.com Women s Cancer Network Web Site: www.wcn.org Toll-Free Gynecologic Cancer
More informationSexual Health in Older Adults
Sexual Health in Older Adults Lauren Carpenter, MD UW Division of Gerontology and Geriatric Medicine VA Puget Sound Geriatrics & Extended Care Objectives > Identify barriers to addressing sexual health
More informationOpening the Door to Intimacy. Carolynn Peterson, RN, MSN, AOCN
Opening the Door to Intimacy Carolynn Peterson, RN, MSN, AOCN What is the largest sex organ in humans? Ways That Cancer or Its Treatment Can Affect Your Sexuality: Physical ability to give and receive
More informationScream Cream. Ingredients: Aminophylline 15-mg, Ergoloid mesylate 0.25-mg, Pentoxifylline 25-mg and L-Arginine 30-mg
At LifeCare Pharmacy we understand that women have different needs at different stages of their lives. Maintaining a healthy and balanced lifestyle can be a difficult struggle. The chronic stress of overly
More informationBreast cancer is the most common malignant tumor in
Menopause: The Journal of The North American Menopause Society Vol. 23, No. 10, pp. 1108-1113 DOI: 10.1097/GME.0000000000000672 ß 2016 by The North American Menopause Society Fractional microablative CO
More informationThe Mona Lisa Touch, a microablative fractionated CO2 laser for vaginal atrophy
The Mona Lisa Touch, a microablative fractionated CO2 laser for vaginal atrophy VVA Lasers basics The MLT treatment Evidence Indications,cautions etc Summary Vulvovaginal Atrophy The new term is GSM- Genitourinary
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationCopyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
28 The Nurse Practitioner Vol. 41, No. 7 www.tnpj.com 2.0 CONTACT HOURS 1.0 CONTACT HOURS Genitourinary syndrome of menopause: A new name for an old condition Abstract: Genitourinary syndrome of menopause
More informationSexuality. The Pharmacologic Treatment of Female Sexual Dysfunction: Future Reality or Wishful Thinking? Risks of Opening the Medicine Cabinet
5 th Annual Meeting of the North American Menopause Society October 5, 4 Washington, DC Low Libido at Midlife: Will the Answer Ever Be in Our Medicine Cabinets? The Pharmacologic Treatment of Female Sexual
More informationThe impact of cancer and cancer treatments on sexuality and what can help. Trish Lymburner, MSW, RSW Lisa Roelfsema, MSW, RSW
The impact of cancer and cancer treatments on sexuality and what can help Trish Lymburner, MSW, RSW Lisa Roelfsema, MSW, RSW 1 Presenter Disclosure Presenters: Lisa Roelfsema, MSW, RSW and Trish Lymburner,
More informationUrinary Tract Infections
Urinary Tract Infections Introduction A urinary tract infection, or UTI, is an infection of the urinary tract. Infections are caused by microbes, including bacteria, fungi and viruses. Microbes are organisms
More informationEvaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-004HR) in Menopausal Women with Moderate to Severe Dyspareunia
Evaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-4HR) in Menopausal Women with Moderate to Severe Dyspareunia Lisa Larkin, MD 1 ; Andrew M Kaunitz, MD 2 ; James Liu, MD
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationPresentation 10 Feb 2, 2019
Addressing Sexual Relationship Concerns for the Patient Treated for Cancer 2019 BREAST HEALTH: A TEAM APPROACH 2/2/2019 SARAH JAX, MA, APRN, AOCNP MINNESOTA ONCOLOGY - PLYMOUTH Objectives Discuss causes
More informationWomen's Cancer & Sexuality Diljeet K. Singh, MD, DrPH CANCER SURVIVOR DAY
Women's Cancer & Sexuality Diljeet K. Singh, MD, DrPH CANCER SURVIVOR DAY Explicit diagrams & anatomy drawings will be used in this lecture Specific treatment techniques will be discussed for sexual problems
More informationResearch Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women
Cronicon OPEN ACCESS PHARMACEUTICAL SCIENCE Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms Bungau S 1, Tit DM 1 *, Fodor K 1
More informationRAISING THE AWARENESS OF GYNAECOLOGICAL CANCER. Penny Bognuda CNS Gynaecologic Oncology ADHB. June 2015.
RAISING THE AWARENESS OF GYNAECOLOGICAL CANCER Penny Bognuda CNS Gynaecologic Oncology ADHB. June 2015. AIMS AND OBJECTIVES OF THE NEXT ½ HOUR. Brief overview of the different types of gynaecological cancers
More informationDHEA, a superior treatment option for vaginal atrophy and menopause symptoms in women
DHEA, a superior treatment option for vaginal atrophy and menopause symptoms in women Dr. Anna Cabeca With aging, menopause, and hormonal changes some 75% of post-menopausal women suffer from vaginal atrophy
More informationSexual Side Aspects of Incontinence - Suburethral Sling Surgery - in Women:
Sexual Side Aspects of Incontinence - Suburethral Sling Surgery - in Women: Irwin Goldstein MD Director, Sexual Medicine, Alvarado Hospital, San Diego, California Clinical Professor of Surgery, University
More informationOne Day Hormone Check
One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationManagement of Urogenital Prolapse of Women in Primary Care. Lizzie McManus MBE RGN RMN Practice nurse Womens health practitioner
Management of Urogenital Prolapse of Women in Primary Care Lizzie McManus MBE RGN RMN Practice nurse Womens health practitioner Primary Care Womens Health Forum www.pcwhf.org.uk Useful websites RCN genital
More informationMenopause and Post Gynecological Reproductive Care
Menopause and Post Gynecological Reproductive Care Nguyet-Cam Vu Lam, MD, FAAFP Associate Program Director St. Luke s Family Medicine Residency 1 Disclosure Dr. Nguyet-Cam Vu Lam has no conflict of interest,
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationNorthwest Rehabilitation Associates, Inc.
Pelvic Health Patient Intake Form Name: Date: Please answer the following questions as honestly and thoroughly as you can. Your responses will help us better understand your condition and provide the best
More information5/3/2016 SEXUALITY: KNOWLEDGE OPENS THE DOOR OBJECTIVES DEFINITIONS CONT. DEFINITIONS
SEXUALITY: KNOWLEDGE OPENS THE DOOR TO COMMUNICATION JILL LIBBESMEIER BSN, RN, OCN OBJECTIVES Understand the differences between sexuality, intimacy, sexual health, and sexual dysfunction Identify how
More informationSexuality in Later Life
National Institute on Aging AgePage Sexuality in Later Life Many people want and need to be close to others as they grow older. This includes the desire to continue an active, satisfying sex life. But,
More informationSexual Concerns. Mental Health Topics
Sexual Concerns A lot of people have concerns about their sex life. Common concerns and problems that affect one or both sex partners Talk to your partner about your include: sexual concerns. n Little
More information-TherapeuticsMD will host a conference call at 8:00 AM EDT today-
FOR IMMEDIATE RELEASE TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY TM (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe
More informationDefinition/Epidemiology Approach to premenopausal and postmenopausal women A couple tricky cases DISCLOSURES. No financial relationships to disclose.
DISCLOSURES RECURRENT URINARY TRACT INFECTIONS No financial relationships to disclose. Anna C. Kirby, MD, MAS Acting Assistant Professor University of Washington Division of Urogynecology Department of
More informationgenitourinary syndrome of menopause Objectives: To evaluate the safety and long-term efficacy of fractional CO2 laser
Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause Abstract Objectives: To evaluate the safety and long-term efficacy of fractional
More informationUrogynecology ICD-9 to ICD-10 Crosswalks
1100 Wayne Ave, Suite 825 Silver Spring, MD 20910 301.273.0570 Fax 301.273.0778 info@augs.org www.augs.org Urogynecology ICD-9 to ICD-10 Crosswalks ICD 9 ICD 9 Description ICD 10 Code ICD 10 Description
More informationOne Day Hormone Check
One Day Hormone Check DOB: Sex: F MRN: Order Number: Completed: Received: Collected: Salivary Hormone Results Estradiol pmol/l >3330.0 Testosterone pmol/l
More informationPostmenopausal women may experience genitourinary
Menopause: The Journal of The North American Menopause Society Vol. 23, No. 1, pp. 000/000 DOI: 10.1097/gme.0000000000000485 * 2015 by The North American Menopause Society Quality of life and sexual function
More informationTherapeutic Cohort Results
Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7
More information